What does MK-677 do? Benefits and evidence
This experimental oral drug raises growth hormone and IGF-1; risks include high blood sugar and swelling.
Also called: Ibutamoren, Ibutamoren mesylate, Ibutamoren mesilate, MK-0677, MK0677, LUM-201, L-163,191.
Growth hormone secretagogues (ghrelin receptor) · Non-peptide ghrelin-receptor agonist and growth hormone secretagogue.
MK-677 is an oral small molecule, not a peptide. Trials found higher growth hormone and IGF-1, but better strength or recovery did not reliably follow. It can raise blood sugar, increase hunger and cause swelling. A hip-fracture trial stopped early over heart-failure concerns. Pediatric growth trials remain separate from adult self-use.
- In a trial of older adults, it raised lean body mass, though strength and function did not improve. (Studied in a trial)
- Studies show it raises growth hormone and IGF-1 in the blood; better strength or recovery did not reliably follow. (Studied in a trial)
- Small, short studies found changes in deep and REM sleep; long-term sleep benefit is unknown. (Studied in a trial)
- People report better sleep and an easier time eating more. (Reported by users)
Uses in the sources
- Studied for lean mass in older adults and men with obesity. More lean mass did not reliably improve strength or function. (Studied in a trial) (source)
- Two hip-fracture trials did not establish better overall recovery. One stopped early over heart-failure concerns. (Studied in a trial) (source)
- Small studies found changes in deep and REM sleep. Long-term benefit for insomnia is unknown. (Studied in a trial) (source)
- Investigational for selected children with GH deficiency. A phase 3 trial is recruiting; there is no approved pediatric dose. (Studied in a trial) (source)
- A 563-person Alzheimer trial raised IGF-1 without slowing clinical decline. (Studied in a trial) (source)
- People report using it for bulking, hunger and sleep. Forum reports cannot separate drug effects from training, diet or other drugs. (Reported by users) (source)
Related to MK-677 (ibutamoren)
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- GHRP-2: A peptide that releases growth hormone and can increase hunger.
- GHRP-6: A peptide studied in growth hormone tests and an experimental stroke combination.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Unapproved ibutamoren capsules (MK-677) found to contain undisclosed anabolic steroid, Therapeutic Goods Administration · 2026
- 503A Categories Update for September 2024, FDA · FDA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting, FDA · 2024
- Anaphylaxis, NHS · NHS · 2023
- Scheduling delegate's final decisions, April 2018, Therapeutic Goods Administration · 2018
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
- EU/3/17/1882 - orphan designation for treatment of growth hormone deficiency, European Medicines Agency
- Information on Select Dietary Supplement Ingredients and Other Substances, FDA
- Search Orphan Drug Designations and Approvals, FDA · FDA
- Supply unlicensed medicinal products (specials), MHRA · MHRA
- Unauthorized workout supplements may pose serious health risks, Health Canada
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.